Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175047 | 1.00 | ALDH1A1 (0.61) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL846416 | 0.91 | GABRA1 (0.74) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL27967224 | 0.89 | NR4A2 (0.57) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL29800593 | 0.89 | NR4A2 (0.54) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL22864631 | 0.89 | NR4A2 (0.54) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL1994694 | 0.86 | ALDH1A1 (0.58) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL830179 | 0.85 | NR4A2 (0.73) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL2050904 | 0.84 | GABRA1 (0.61) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL995637 | 0.84 | NR4A2 (0.70) | ALDH1A1HPGDKMT2ANR4A2KDM4E | |
| SCHEMBL3177863 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GABRA1GABRB2GABRB1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4110327-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484947-A | Selective Androgen Receptor Degrader (SARD) ligands and methods of use thereof | 田纳西大学研究基金会 | 2022-12-16 | — | — | CN | disclosed |
| WO-2007058504-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES, LTD. (KR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | ALDH1A1 1972/4885GABRA1 1279/4885GABRB2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.